Migraine disease: evolution and progression by unknown
Introduction
The role of the brain in migraine disorders remains
unclear, although recent findings link migraine to other
neurological conditions, i.e., hemiplegic migraine is allel-
ic with episodic shares common genetic assessment with
ataxias and cerebellar disorders [1]. This possible link
between different pathological conditions residing primar-
ily in the central nervous system (CNS) supports the
hypothesis that migraine represents a complex disease
with episodic signs and symptoms variably manifesting
during the lifetime of migraine patients. The international
guidelines for diagnosing migraine provide criteria for
different attacks, although some of the proposed subtypes
may be present in the same patient, suggesting that the
disease may have different clinical manifestations [2] and
that the guidelines do not reflect the need of diagnosing
complex phenotypes, apart from pooling together differ-
ent diagnostic codes.
Unmasking latent migraine
Migraine is a heterogeneous disorder. In fact, there is
extreme variability as far as several features are concerned,
such as age at onset, presence or not of focal neurological
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Abstract Migraine is a complex
pathology and it should be regarded
as a disease evolving during the
lifetime along with other comorbid
conditions. Migraine susceptibility
may be unmasked by exogenous
substances and the occurrence of
migraine attacks may change fol-
lowing drugs given for therapeuti-
cal purposes. The evolution of
migraine should be followed up
because childhood migrainous man-
ifestations may vary over the years
and an earlier diagnosis may not
apply later on.
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signs (the aura), the evolution from adolescence to adult-
hood and the changes induced by exogenous substances.
Family history of migraine in subjects who are apparently
not affected may play a significant role when they receive
migraine-triggering substances, such as hormones or nitric
oxide (NO) donors. These may, in fact, trigger migraine-
like headache in subjects without personal history of
migraine, but harbouring the susceptibility in their family
[3, 4]. The onset of migraine attacks following oral contra-
ceptives (OCs) should be regarded as a possible side effect
of OCs in prone women [5]. Endogenous hormones seem
to act in a different manner in migraine women. Migraine
without aura (MO) is more likely to appear for the first
time at puberty and to be triggered by declining oestro-
gens, whereas migraine with aura (MA) more likely begins
with sustained high sex hormone levels, during pregnancy
or with oestrogen replacement [6]. The influence of OCs
does not appear to be different in patients who have only
MO and those who have MA+MO [7].
Among NO donors, nitroglycerin (NTG) has under-
gone extensive experimental investigation in the neuro-
logical field, because typical headaches develop in
migraineurs (but not normals) with a 4–6 h latency after
its administration [8]. In experimental animal models,
NTG administration induces an up-regulation of pro-
inflammatory genes (iNOS, interleukin-6, interleukin-1),
mast cell and macrophage activation, with a subsequent,
delayed inflammatory reaction in the dura mater of the rat
(4–6 h) [9]. This could be the mechanism through which
NTG induces the migraine attack in humans.
Migraine-like headache attacks also occur in non-
migraineurs with family history of migraine, following
NO-donor administration, therefore the susceptibility to
the disorder can be unmasked using these substances. This
is of extreme relevance in patients who receive nitrates for
therapeutic purposes.
Taken together, these synthetically reported observa-
tions lead to an outline of the concept that migraine has an
“organic” substrate on which the clinical pattern may be
modulated by exogenous or endogenous substances.
Migraine and comorbid conditions
The heterogeneity of migraine also implies that there is an
association with other neurological, psychiatric and car-
diovascular diseases, the most common being epilepsy,
cerebrovascular disorders, anxiety/depression, arterial
hypertension, mitral valve prolapses and patent foramen
ovale. The association is not coincidental and it may be
due to a common genetic substrate and to the presence of
different mutations in the same gene [10]. The hypothesis
envisages common neurobiological mechanisms influenc-
ing the full expression of the clinical phenotype [11]. In
this view, deranged brain oxidative metabolism, abnormal
neuronal excitability, possibly due to altered membrane
ion channels, and functional changes in receptor compo-
nents, along with environmental factors, represent the
mechanisms underlying the spectrum of migraine and
comorbid conditions and the continuum among these dis-
orders. Ion channel pathology, mitochondrial disorders
and other gene mutations received attention in the genetic
era and linked migraine to other paroxysmal episodic phe-
nomena, raising the question of whether migraine is a
genetically determined disorder [12, 13].
There is increasing concern about migraine and the
risk of ischaemic stroke [14], although further studies are
needed to explore the mechanism of this potential associ-
ation. This topic seems crucial when OCs are prescribed
in female migraine patients. There is no clear evidence
that OCs increases the risk of stroke, however discontinu-
ation of the substances is prudent in these patients, name-
ly in the presence of other risk factors, smoking habit or
middle age, for instance [14, 15]. Similar actions should
be taken when screening patients to be treated with vaso-
constrictor agents, such as ergots and the triptans. To sum-
marise, accurate recognition of comorbid diseases, as well
as increasing the list of differential diagnoses, provides
epidemiological clues to the fundamental pathophysiolo-
gy of migraine, and creates therapeutic opportunities
and/or imposes therapeutic limitations.
Migraine evolution: born to be migrainous
Cyclic vomiting, abdominal migraine and paroxysmal
vertigo represent precursors of adulthood migraine [2] to
support the hypothesis that migrainous disorders are pre-
sent early during the lifetime. The above manifestations
seem to represent unspecific and low-grade paroxysmal
events as if the brain would not yet be able to configure a
clear migraine attack. As long as the “visceral organ
brain” [16] develops, it becomes able to clearly organize
a fully blown migraine attack and the former episodes
tend to decrease and disappear. There is evidence that
they are neurobiologically related to migraine [17, 18]
and therefore the recognition of a migraine disorder
should be considered in young children prior to submit-
ting them to instrumental diagnostic procedures.
Interestingly, the diagnosis of MA [2, 19] in adolescents
is clearly unstable [20] and a large proportion of them
convert to “probable migraine without aura” [2], previ-
ously coded as “migrainous disorder not fulfilling the cri-
teria” [19], at 3-year follow up.
306
Migraine attacks tend to disappear following severe trau-
matic brain injury [21] and to recur after a certain degree of
cognitive functioning is regained, thus suggesting that a cer-
tain degree of “high level” pain processing is needed in order
to perceive the migraine pain along with premonitory and
accompanying symptoms and the aura as well. Therefore,
the more severe the brain damage, the later the recovery of a
fully developed migraine attack. Furthermore, neurodegen-
erative diseases presenting with focal brain damage in
dopaminergic areas, such as substantia nigra in Parkinson’s
disease, may somehow shorten the lifetime clinical course of
migraine, suggesting that an imbalance in the nociceptive
system has an effect on migraine mechanisms [22].
According to the above consideration, the question of
whether migraine has an evolutionary meaning arises
[23]. Is migraine a natural selection product? Is migraine
an alarm system to protect the brain from inner injuries?
Trying to answer those questions will be one of the routes
to travel to find interesting topics for understanding the
evolution of human brain development.
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